XOMA Royalty (XOMA) Return on Capital Employed (2011 - 2026)
XOMA Royalty (XOMA) reported Return on Capital Employed of 5.11% for Q1 2026, up 1887.0% on a YoY basis from 0.26% in Q1 2025, and up 181.35% sequentially from 6.29% in Q2 2025.
XOMA Royalty (XOMA) Return on Capital Employed (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Return on Capital Employed data on file, last reported at 5.11% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1887.0% year-over-year to 5.11%; the trailing twelve-month figure through Mar 2026 stood at 5.11% (up 1887.0% YoY), and the FY2025 full-year result was 5.37%, up 2502.0% from the prior year.
- Return on Capital Employed climbed to 5.11% in Q1 2026, from 6.29% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.13% in Q1 2022 to a low of 26.2% in Q4 2023.
- A 5-year average of 10.85% and a median of 18.3% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 3779 bps in 2023 and soared 1887 bps in 2026, its largest moves.
- Tracing XOMA's Return on Capital Employed over 5 years: stood at 12.76% in 2022, then plunged by 105 bps to 26.2% in 2023, then increased by 23 bps to 20.2% in 2024, then jumped by 69 bps to 6.29% in 2025, then jumped by 181 bps to 5.11% in 2026.
- Business Quant data shows XOMA's Return on Capital Employed at 5.11% in Q1 2026, 6.29% in Q2 2025, and 13.76% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 5.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.11% |
| Jun 30, 2025 | -6.29% |
| Mar 31, 2025 | -13.76% |
| Dec 31, 2024 | -20.20% |
| Sep 30, 2024 | -24.82% |
| Jun 30, 2024 | -20.12% |
| Mar 31, 2024 | -18.30% |
| Dec 31, 2023 | -26.20% |
| Sep 30, 2023 | -24.55% |
| Jun 30, 2023 | -21.79% |
| Mar 31, 2023 | -20.10% |
| Dec 31, 2022 | -12.76% |
| Sep 30, 2022 | 13.24% |
| Jun 30, 2022 | 13.62% |
| Mar 31, 2022 | 14.13% |
| Dec 31, 2021 | 12.93% |
| Sep 30, 2021 | 8.72% |
| Jun 30, 2021 | 9.62% |
| Mar 31, 2021 | 10.60% |
| Dec 31, 2020 | 13.32% |